Skip to main content
GutCited

Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome.

Piero Portincasa, Leonilde Bonfrate, Maria Lia Lia Scribano, Anna Kohn, Nicola Caporaso et al.
RCT Journal of gastrointestinal and liver diseases : JGLD 2016 96 цитирований
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'pmid\u003D27308645'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Тип исследования
Randomized Controlled Trial
Размер выборки
121
Популяция
IBS patients (multicenter)
Длительность
4 weeks
Вмешательство
Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome. curcumin + fennel essential oil (2 capsules bid)
Препарат сравнения
placebo
Первичный исход
IBS symptom score and quality of life
Направление эффекта
Positive
Риск систематической ошибки
Low

Abstract

BACKGROUND AND AIMS: Irritable Bowel Syndrome (IBS) patients still require effective treatment. The anti-inflammatory property of curcumin and the antispasmodic and carminative effect of fennel suggests that combination of these nutraceutical compounds would be useful in functional bowel disorders including IBS. We assessed the efficacy and tolerability of a combination of curcumin and fennel essential oil (CU-FEO) in IBS symptoms relief. METHODS: 121 patients with mild-to-moderate symptoms of IBS defined by an Irritable Bowel Syndrome- symptom severity score (IBS-SSS) 100-300 and abdominal pain score 30-70 on a 100 mm Visual Analogue Scale (VAS), were randomly assigned to CU-FEO or placebo (2 capsules b.d. for 30 days). Primary endpoint was the mean decrease of IBS-SSS at the end of the treatment corrected for the mean baseline score (relative decrease). The impact of the treatment on quality of life was assessed through IBS-QoL questionnaire. RESULTS: CU-FEO was safe, well-tolerated and induced symptom relief in patients with IBS; a significant decrease in the mean relative IBS-SSS was observed after 30 days of treatment (50.05 +/- 28.85% vs 26.12 +/- 30.62%, P<0.001). This result matched the reduction of abdominal pain and all the other symptoms of IBS-SSS. The percentage of symptom-free patients was significantly higher in the CU-FEO than in the placebo group (25.9% vs. 6.8%, P = 0.005). All domains of IBS-QoL improved consistently. CONCLUSION: CU-FEO significantly improved symptoms and quality of life in IBS patients over 30 days.

Кратко

CU-FEO significantly improved symptoms and quality of life in IBS patients over 30 days and matched the reduction of abdominal pain and all the other symptoms of IBS-SSS.

Used In Evidence Reviews

Similar Papers